MHRA Warns: ACE Inhibitor-Induced Angioedema May Be Bradykinin-Mediated and Unresponsive to Standard Anaphylaxis Treatment
核心洞察
The UK MHRA is strengthening warnings that ACE inhibitor-associated angioedema (搜索) can occur after weeks to years of use, with approximately half of cases with reported time-to-onset occurring 30 days or more after treatment initiation.
Healthcare professionals must distinguish between histamine-mediated and bradykinin-mediated angioedema (搜索), as bradykinin-mediated cases do not respond to standard anaphylaxis treatments including adrenaline.
UK Yellow Card data and manufacturer reports confirm that 20–30% of angioedema (搜索) cases occur after at least 30 days of therapy, with fatal cases involving airway compromise reported after prolonged ACE inhibitor use.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued an urgent safety communication advising healthcare professionals to recognise the critical distinction between bradykinin-mediated and histamine-mediated angioedema (搜索) in patients taking ACE inhibitors (搜索), as the two conditions require fundamentally different treatment approaches and bradykinin-mediated cases do not respond to standard anaphylaxis interventions.
The regulatory action comes as product information for all ACE inhibitors (搜索) is being updated to strengthen warnings on the risk of delayed-onset angioedema (搜索), which may occur after weeks to years of continuous use. ACE inhibitors are widely prescribed for hypertension, heart failure, post-myocardial infarction management, diabetic nephropathy, and cardiovascular risk reduction.
Delayed Onset: A Key Clinical Challenge
A review of UK Yellow Card data up to and including 10 June 2026 revealed that approximately one-half of angioedema (搜索) cases with reported time-to-onset occurred 30 days or more after initiation of treatment. Manufacturer data further indicated that around 20–30% of reported cases occurred after at least 30 days of therapy. This pattern of delayed onset is more strongly associated with bradykinin-mediated angioedema.
"Published literature describes bradykinin-mediated angioedema (搜索) occurring weeks to many years after initiation, including cases reported after several years of continuous use," the MHRA noted. Fatal cases, although rare, have involved airway compromise and have occurred after prolonged ACE inhibitor treatment.
Distinguishing Between Two Mechanisms
Angioedema (搜索) is characterised by localised swelling of subcutaneous or submucosal tissues. Unlike histamine-mediated (allergic) angioedema, bradykinin-mediated angioedema usually occurs without urticaria and typically has a slower onset. Symptoms may involve the tongue, lips, and upper airway, and can be life-threatening. Other symptoms can include gastrointestinal pain and cramps.
The MHRA emphasised that bradykinin-mediated angioedema (搜索) is unlikely to respond to standard anaphylaxis treatments including adrenaline (epinephrine). Lack of response to such treatments should prompt immediate consideration of a bradykinin-mediated mechanism, with treatment informed by clinical protocols.
At-Risk Populations
Certain populations may be at increased risk of angioedema (搜索) associated with ACE inhibitors (搜索), including older adults, women, people who smoke, and patients of Black or African Caribbean ethnicity.
Clinical Management Guidance
Current clinical guidance used in emergency medicine recognises ACE inhibitors (搜索) as a leading cause of non-allergic angioedema (搜索) and advises consideration of bradykinin-mediated mechanisms when standard treatment is ineffective. The guidance emphasises prompt discontinuation of the ACE inhibitor, close airway monitoring, and early specialist involvement in severe or life-threatening cases. Additional investigations, such as C4 level testing, may support identification of non-allergic causes and help guide management.
If angioedema (搜索) is suspected in a patient taking an ACE inhibitor, healthcare professionals should discontinue the ACE inhibitor immediately and not restart it. Patients should be advised to seek urgent medical attention if they develop swelling of the face, lips, tongue, or throat, or experience difficulty breathing or swallowing.
Regulatory Updates Underway
The MHRA is implementing updates to the Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PIL) in a phased approach. These updates will strengthen warnings and improve communication on the risk of delayed-onset angioedema (搜索) and the potential for standard anaphylaxis treatments to be ineffective. The updates are currently in progress and will be implemented over the coming months.
In Hong Kong, the Department of Health has received 26 cases of adverse drug reaction reports related to ACE inhibitors (搜索), of which one case was reported as angioedema (搜索). The matter will be discussed by the Registration Committee of the Pharmacy and Poisons Board of Hong Kong. ACE inhibitor products are registered in Hong Kong as prescription-only medicines.